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key objective over the next two or three years is to
create a dynamic environment for research and devel-
opment within which doctors can work with suppliers
and others on the new electronic services, can continue
to innovate after the initial services have been
delivered, and can, if necessary, take part in decisions to
amend or stop unsuccessful developments.
Staff working on the programme face a dilemma,
however. How can they retain the advantages of the
central procurement arrangements while at the same
time encouraging localism? The answer may be for
Connecting for Health, the agency responsible for the
programme, to become a regulator. The agency could
stop directing implementation centrally and could
become responsible for encouraging good working
relationships between suppliers and clinicians. In this
way the agency would retain its role in monitoring
compliance with multibillion pound contracts while
letting clinicians and suppliers get on with
development. It would also have an ongoing role in
protecting the wider public interest on matters such as
patient confidentiality. This arrangement might help
to allay some clinicians’ natural fears that their
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Antipyretic drugs for children
There’s still not enough evidence to support prescribing paracetamol and ibuprofen
in combination or alternately
Fever is common in children
1 and can cause
distress, parental anxiety, and—in some parents—
“fever phobia.”2 Rationales for treating childhood
fever include relieving distress (allowing the child to
sleep, rest, or feed) and lowering temperature, often in
the hope of reducing the risk of febrile convulsions.
Non-pharmacological treatments include loosening
clothing, reducing the ambient temperature, and
encouraging the child to take fluids. The pharmacologi-
cal options are paracetamol and ibuprofen, and parents
commonly give both drugs to a child with fever.3 But
should these drugs be used together, or alternately, and
for which children, and at what dose and frequency?
Advice is inconsistent, leading to confusion and frustra-
tion among parents, nurses, and doctors.
Both drugs are licensed and widely purchased over
the counter in Europe for children: sales in 2004 were
£128m for paediatric ibuprofen and £277m for
paracetamol (€186m and €403m, $233m and $504m;
personal communication, Boots Healthcare Interna-
tional). Paracetamol and ibuprofen exert their effects at
differing points in the pyrogenic pathways,4 so
synergistic action is plausible.
We searched Medline (1966 to March 2006), the
Cochrane database, and our own databases and found
three studies comparing a combination of paracetamol
or ibuprofen with separate use.5–7 The first studied 89
children admitted to hospital in India with axillary
temperatures greater than 38.5°C.5 Children received
ibuprofen 10 mg/kg singly or in combination with
paracetamol 10 mg/kg, each three times daily. The
paracetamol-ibuprofen combination was more effec-
tive than paracetamol alone from 0.5 hours to 2 hours
and less effective from 10 hours to 24 hours, but the
temperature differences amounted to less than 1°C
and were not statistically significant.
The second study randomised 123 children present-
ing to a UK emergency department with tympanic tem-
peratures ≥ 38°C to receive paracetamol 15 mg/kg or
ibuprofen 5 mg/kg, or both, and measured tympanic
temperature at one hour.6 The investigators defined a
clinically important temperature difference as ≥ 1°C.
Although they found a statistically significant difference
(P = 0.023) between all treatments, the temperature
difference between the groups receiving combined
treatment and paracetamol only was 0.35°C and
between those receiving combined treatment and
ibuprofen only was 0.25°C. The confidence intervals
exclude the original target difference of 1°C and so, if
the 1°C threshold is accepted, the study was able to rule
out a clinically important difference at one hour.Neither
the Indian nor UK studies measured symptoms
associated with fever.
The third study randomised 464 children present-
ing to Israeli ambulatory care centres with rectal
temperatures of ≥ 38.4°C to receive paracetamol
12.5 mg/kg every six hours or ibuprofen 5 mg/kg
every eight hours or both alternating four hourly.7 Irre-
spective of their intervention group, all children
received a double loading dose of either paracetamol
or ibuprofen. Rectal temperatures and distress scores
were measured (at times determined by the parents)
three times daily for three days and the thermometry
outcome used for the analyses was the maximum tem-
perature recorded. The investigators found differences
lasting three days in temperatures (range 0.8°C to
1.1°C, all P < 0.001) and distress scores (all P < 0.001)
between the alternating and monotherapy groups.
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The children in these studies were probably more
unwell than most febrile children managed at home.
Collating the evidence is limited by inconsistent doses
and thermometry methods, and only one study meas-
ured the children’s discomfort.7 The Indian study sug-
gests there is no advantage in using both drugs rather
than one, but it may have been underpowered. The UK
study helps our understanding of early treatment
effects, but not those beyond one hour. The Israeli
study is difficult to interpret because half the children
in the monotherapy groups received both medicines in
the first 24 hours and parents determined the timing
of thermometry and recording of distress scores.
Evidence on safety is also limited. Renal failure is
associated with the use of ibuprofen in dehydrated chil-
dren,8 and the combination of both drugsmay, in theory,
cause renal tubular necrosis as ibuprofen inhibits the
production of renal glutathione, which detoxifies and
prevents the accumulation of a nephrotoxic metabolite
of paracetamol.9 However, two studies have shown no
difference in renal function comparing combined with
separate use,5 7and the website of the Committee on
Safety of Medicines has no reports of adverse events.10
There are other important gaps in the evidence.
Most surprisingly, there is an absence of evidence of
effectiveness for monotherapies compared with physi-
cal methods of reducing fever or placebo.11 Further-
more, future research should measure the outcomes
that are important to parents—namely, symptoms
associated with fever.
The definition of a clinically useful difference in
temperature after treatment is debatable and, given that
the maximum times for antipyretic activity differ for
paracetamol and ibuprofen, the timing of measuring the
difference in temperature is crucial to the validity of the
comparison. The best method to ensure fairness is con-
tinuous thermometry, which generates an average time
spent under a fever threshold after treatment and has
been used in one study to date.12 More research using
maximum therapeutic doses, continuous thermometry
and measuring symptoms associated with fever is
under way (www.controlled-trials.com/isrctn/trial/|/0/
26362730.html), but until such evidence is available, the
role of combined antipyretics is uncertain.
Given that the absence of evidence from trials is at
odds with strongly held parental beliefs in many cases,
and given the desire among parents and clinicians to
do something when faced with febrile children, it
seems churlish to conclude that combined treatment
should be withheld from all children. But parents
should be advised to use the minimum treatment nec-
essary. Using two drugs always has some disadvantages:
increased risks of overdosing, underdosing, and
adverse effects; increased costs; greater medicalisation
and—in this case—an associated risk of exacerbating
fever phobia.
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Psychological interventions for treatment of adult
sex offenders
Treatment can reduce reoffending rates but does not provide a cure
Sexual offending is a public health issue and asocial problem. Medical practitioners mightassume from the volume of work published on
treatments for sex offenders that clinically effective
treatments are available. Indeed, psychological treat-
ment is often mandated in the sentencing decision for
sexual offenders. Yet the effectiveness of treatments is
debated, and evidence for the efficacy of sex offender
treatment programmes is often too readily accepted
uncritically.1
In conducting a Cochrane meta-analysis on the
effects of such psychological interventions we found
nine trials that were well conducted in terms of
randomisation, blinding, loss to follow-up, and
analysis.2 These included randomised controlled trials
with a total of 567 male offenders, 231 of whom were
followed up for a decade.
The results indicated that studies on behavioural
treatments were too small to be informative, although
statistically significant improvements were recorded
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